Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00031187 · ClinicalTrials.gov registry record · Phase 2
Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer
A Phase 2 study, sponsored by Seagen.
- Completed
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
NCT00031187 is a Phase 2 study that has completed, run by Seagen. The registered enrollment target is 160 participants.
The verdict
NCT00031187, a Phase 2 study, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
Study Summary
SGN-15 is being investigated for therapy of patients with prostate cancer in combination with the cytotoxic agent, Taxotere. The study is an open label, randomized phase II study for patients with documented hormone refractory prostate cancer who have not had any prior therapy with Taxotere or Novantrone. Both SGN-15 and Taxotere will be administered weekly over two 6 week courses separated by a 2 week rest period.
Interventions
- DRUG SGN-15 (cBR96-doxorubicin immunoconjugate)
- DRUG Taxotere (docetaxel)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2000-10 |
| Est. Completion | 2003-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00031187
The ClinicalTrials.gov registry entry for NCT00031187 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SGN-15 (cBR96-doxorubicin immunoconjugate) is the first listed.
NCT00031187 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00031187 about?
NCT00031187 is a clinical study titled "Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer". SGN-15 is being investigated for therapy of patients with prostate cancer in combination with the cytotoxic agent, Taxotere. The study is an open label, randomized phase II study for patients with documented hormone refractory prostate cancer who have not had any prior therapy with Taxotere or Novan...
What is the current status of trial NCT00031187?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2000-10. Estimated completion is 2003-07.
What interventions are being tested in trial NCT00031187?
The interventions under investigation include: SGN-15 (cBR96-doxorubicin immunoconjugate) (DRUG), Taxotere (docetaxel) (DRUG).
Who is sponsoring clinical trial NCT00031187?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.